Mark Coleman, Director at Axsome Therapeutics, Inc. (AXSM), bought 500 shares at $58.15 ($29K) on 2021-05-12, disclosed to the SEC on 2021-05-13.
Open-market purchase of $29k AXSM by Director. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade C.
Nothing distinguishes this filing.
| Filing → |
| AXSM | SELL | 2026-02-27 | $4.0M | — | Filing → |
| AXSM | BUY | 2025-09-09 | $263K | — | Filing → |
| AXSM | SELL | 2025-05-29 | $1.6M | — | Filing → |